UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 218

Sortiert nach

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

Journal of clinical oncology, 2012-08, Vol.30 (22), p.2718-2724

2012

Volltextzugriff (PDF)

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Nature communications, 2024-03, Vol.15 (1), p.1985-1985, Article 1985

2024

Volltextzugriff (PDF)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments

Cancers, 2023-03, Vol.15 (6), p.1738

2023

Volltextzugriff (PDF)

PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes

International journal of gynecological cancer, 2017-03, Vol.27 (3), p.554-561

2017

Volltextzugriff (PDF)

Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives

Cancers, 2021-09, Vol.13 (19), p.4840

2021

Volltextzugriff (PDF)

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

Journal of clinical oncology, 2016-03, Vol.34 (7), p.706-713

2016

Volltextzugriff (PDF)

Véronique Trillet-Lenoir

Bulletin du cancer, 2023-11, Vol.110 (11), p.1227-1228

Freyer, Gilles

2023

Volltextzugriff (PDF)

Ovarian Cancer in Elderly Patients

Freyer, Gilles

1, 2015

Volltextzugriff (PDF)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers

Cancers, 2022-01, Vol.14 (3), p.599

2022

Volltextzugriff (PDF)

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

BMC cancer, 2011-11, Vol.11 (1), p.478-478, Article 478

2011

Volltextzugriff (PDF)

COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study

Cancers, 2021-10, Vol.13 (21), p.5283

2021

Volltextzugriff (PDF)

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Breast (Edinburgh), 2024-04, Vol.74, p.103681-103681, Article 103681

2024

Volltextzugriff (PDF)

Methods and Designs of Modern Breast Cancer Confirmatory Trials

Cancers, 2021-06, Vol.13 (11), p.2757

2021

Volltextzugriff (PDF)

Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study

Oncotarget, 2017-10, Vol.8 (50), p.87980-87996

2017

Volltextzugriff (PDF)

Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives

Cancers, 2020-08, Vol.12 (9), p.2414

2020

Volltextzugriff (PDF)

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas

International journal of gynecological cancer, 2014-11, Vol.24 (9 Suppl 3), p.S117-S122

2014

Volltextzugriff (PDF)

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Cancers, 2021-11, Vol.13 (23), p.6014

2021

Volltextzugriff (PDF)

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.319-327

2018

Volltextzugriff (PDF)

Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL)

Cancers, 2021-12, Vol.14 (1), p.29

2021

Volltextzugriff (PDF)

Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Nature communications, 2024-06, Vol.15 (1), p.4753-4753

2024

Volltextzugriff (PDF)

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study

Drugs -- real world outcomes, 2023-06, Vol.10 (2), p.207-213

2023

Volltextzugriff (PDF)

First-Line Therapy in Ovarian Cancer Trials

International journal of gynecological cancer, 2011-05, Vol.21 (4), p.756-762

2011

Volltextzugriff (PDF)

Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer With High-Dose Radiation and Oxaliplatin-Containing Regimen: The Lyon R0–04 Phase II Trial

Journal of clinical oncology, 2003-03, Vol.21 (6), p.1119-1124

2003

Volltextzugriff (PDF)

1 – 25 von 218

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(184)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Life Sciences & Biomedicine
(125)
Oncology
(108)
Humans
(106)
Female
(75)
Aged
(57)
Middle Aged
(43)
Chemotherapy
(40)
Adult
(36)
Male
(35)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Ovarian Cancer
(31)
Aged, 80 And Over
(29)
Cancer
(28)
Life Sciences
(27)
Pharmacology & Pharmacy
(27)
Tumors
(26)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(25)
Pharmacology. Drug Treatments
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments

PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes

Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

Véronique Trillet-Lenoir

Ovarian Cancer in Elderly Patients

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study

The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Methods and Designs of Modern Breast Cancer Confirmatory Trials

Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study

Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients

Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program

Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL)

Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study

First-Line Therapy in Ovarian Cancer Trials

Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer With High-Dose Radiation and Oxaliplatin-Containing Regimen: The Lyon R0–04 Phase II Trial

Suchergebnisse filtern